莎普愛思(603168.SH):擬繼續推進強身藥業100%股權掛牌出售相關事宜
格隆匯 1 月 6日丨莎普愛思(603168.SH)公佈,2020年12月21日,上海聯合產權交易所啟動下一輪掛牌轉讓程序,掛牌公吿期為2020年12月22日至2021年1月5日,掛牌底價為13679.97萬元。截止2021年1月5日,強身藥業100%股權公開掛牌信息披露期滿,本輪掛牌轉讓未徵集到意向受讓方。
考慮到截至目前強身藥業股權轉讓掛牌仍未徵集到受讓方,為提高莎普愛思強身藥業有限公司股權轉讓工作的推進效率,公司於2021年1月6日召開第四屆董事會第十八次會議(臨時會議),審議通過了《關於繼續推進全資子公司100%股權掛牌出售相關事宜的議案》,董事會同意繼續推進強身藥業股權轉讓掛牌事宜,調整掛牌條件後重新掛牌,包括但不限於向下調整轉讓底價、變更轉讓條件等,具體掛牌方案由公司管理層根據市場情況及公司實際情況決定。待受讓方確定後,公司將另行召開董事會審議交易對象、價格及相應產權轉讓合同條款並進一步提交給股東大會審議,股東大會審議通過後公司將與受讓方簽訂相應產權轉讓合同。
上述調整的最終方案、產權交易合同的簽訂及生效以另行召開的股東大會審議通過為前提。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.